Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 16/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GALR3 | O60755 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005612 | 1.00 | ADK (1.00) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL14111715 | 1.00 | ADK (1.00) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL8332076 | 1.00 | ADK (1.00) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL20418988 | 1.00 | ADK (1.00) | ADKSLC29A1DOT1LNPC1GALR3 | |
| SCHEMBL8330784 | 0.91 | ADK (0.83) | ADKSLC29A1 | |
| SCHEMBL8332793 | 0.91 | ADK (0.83) | ADKSLC29A1 | |
| SCHEMBL8332340 | 0.91 | ADK (0.83) | ADKSLC29A1 | |
| SCHEMBL2038994 | 0.89 | ADK (1.00) | ADKSLC29A1 | |
| SCHEMBL4018428 | 0.87 | ADK (0.77) | ADKSLC29A1 | |
| SCHEMBL8331139 | 0.86 | ADK (1.00) | ADKSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-7405204-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405204-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405204-B2 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1853618-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-11-09 | — | — | US | disclosed |
| US-20060241064-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-10-26 | — | — | US | disclosed |
| WO-2006093987-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | TYMP, PNP, NSUN2 | ADK 944/4885SLC29A1 5/4885DOT1L 2889/4885 |
| US-20060241064-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADK 190/4885SLC29A1 36/4885DOT1L 2129/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | ADK 371/4885SLC29A1 955/4885DOT1L 2516/4885 |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | PNP, TYMP, NSUN2 | ADK 365/4885SLC29A1 16/4885DOT1L 2510/4885 |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | PNP, TYMP, NSUN2 | ADK 365/4885SLC29A1 16/4885DOT1L 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.